Results 11 to 20 of about 787,124 (352)

TYROSINE KINASE INHIBITORS AND INTERFERON

Mediterranean Journal of Hematology and Infectious Diseases, 2014
The use of interferon-a (INF) in chronic myeloid leukemia, when it started in the 80s, was considered as a breakthrough in the therapy of this disease; INF administered alone or in combination with aracytine was the standard choice for treatment for
Maria Dimou, Panagiotis Panagiotidis
doaj   +4 more sources

TYROSINE KINASE INHIBITORS AND PREGNANCY

Mediterranean Journal of Hematology and Infectious Diseases, 2014
The management of patients with chronic myeloid leukemia (CML) during pregnancy has became recently a matter of continuous debate.  The introduction of the Tyrosine Kinase Inhibitors (TKIs) in clinical practice has dramatically changed the prognosis of ...
Elisabetta Abruzzese, Malgorzata Monika Trawinska, Paolo De Fabritiis, Alessio Pio Perrotti   +3 more
doaj   +5 more sources

mTORC2 is a tyrosine kinase [PDF]

Cell Research, 2015
The mammalian target of rapamycin (mTOR), a protein kinase, is the centre of huge attention due to its importance in intracellular signaling and in health and disease. In their recent study, Yin et al. show that mTOR can regulate signaling through the insulin-like growth factor 1 receptor and that it possesses a new enzymatic activity - the ability to ...
Christopher G. Proud, Xuemin Wang
openaire   +2 more sources

Tyrosine Kinase Receptors in Oncology [PDF]

International Journal of Molecular Sciences, 2020
Tyrosine kinase receptors (TKR) comprise more than 60 molecules that play an essential role in the molecular pathways, leading to cell survival and differentiation. Consequently, genetic alterations of TKRs may lead to tumorigenesis and, therefore, cancer development.
Jorge Esteban-Villarrubia, Juan José Soto-Castillo, Javier Pozas, María San Román-Gil, Inmaculada Orejana-Martín, Javier Torres-Jiménez, Alfredo Carrato, Teresa Alonso-Gordoa, Javier Molina-Cerrillo   +8 more
openaire   +4 more sources

Tyrosine kinases in rheumatoid arthritis [PDF]

Journal of Inflammation, 2011
Rheumatoid arthritis (RA) is an inflammatory, polyarticular joint disease. A number of cellular responses are involved in the pathogenesis of rheumatoid arthritis, including activation of inflammatory cells and cytokine expression. The cellular responses involved in each of these processes depends on the specific signaling pathways that are activated ...
Hiroshi Okamoto, Akiko Kobayashi
openaire   +4 more sources

Nanomedicine of tyrosine kinase inhibitors

Theranostics, 2021
Recent progress in nanomedicine and targeted therapy brings new breeze into the field of therapeutic applications of tyrosine kinase inhibitors (TKIs). These drugs are known for many side effects due to non-targeted mechanism of action that negatively impact quality of patients' lives or that are responsible for failure of the drugs in clinical trials.
Zita Goliasova, Petr Michalek, Petr Michalek, Veronika Smidova, Zbynek Heger, Zbynek Heger, Vojtech Adam, Vojtech Adam, Petr Hodek, Tomas Eckschlager   +9 more
openaire   +4 more sources

QTC Changes Associated with Tyrosine Kinase Inhibitors in Cancer Patients

Pakistan Armed Forces Medical Journal, 2022
Objective: To look for QTc changes associated with Tyrosine Kinase inhibitors and factors related to these changes among patients suffering from cancer. Study Design: Comparative cross-sectional study.
Rahimullah Khattak, Riaz Ahmad, Muhammad Nadeem, Huma Amjad, Amjad Khan, Ibtisam .   +5 more
doaj   +1 more source

ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK

Frontiers in Pharmacology, 2022
Hyperactivation of Bruton’s tyrosine kinase (BTK) or interleukin-2-inducible T cell kinase (ITK) has been attributed to the pathogenesis of B-cell lymphoma or T-cell leukemia, respectively, which suggests that Bruton’s tyrosine kinase and interleukin-2 ...
Peiran Song, Peiran Song, Gang Bai, Shingpan Chan, Tao Zhang, Linjiang Tong, Yi Su, Yanyan Shen, Yi Chen, Yingqiang Liu, Mengzhen Lai, Mengzhen Lai, Yi Ning, Haotian Tang, Yan Fang, Yi Chen, Ke Ding, Jian Ding, Jian Ding, Hua Xie, Hua Xie, Hua Xie   +21 more
doaj   +1 more source

Tyrosine Kinase Inhibitors for the Elderly [PDF]

Journal of Cancer, 2016
Until few years ago non-specific cytotoxic agents were considered the tip of the arrow as first line treatment for lung cancer. However; age > 75 was considered a major drawback for this kind of therapy. Few exceptions were made by doctors based on the performance status of the patient.
Hohenforst-Schmidt, Wolfgang, Zarogoulidis, Paul, Steinheimer, Michael, Benhassen, Naim, Tsiouda, Theodora, Baka, Sofia, Yarmus, Lonny, Stratakos, Grigoris, Organtzis, John, Pataka, Athanasia, Tsakiridis, Kosmas, Karapantzos, Ilias, Karapantzou, Chrysanthi, Darwiche, Kaid, Zissimopoulos, Athanasios, Pitsiou, Georgia, Zarogoulidis, Konstantinos, Man, Yan-Gao, Rittger, Harald   +18 more
openaire   +4 more sources

The nucleotide and partial amino acid sequences of rat fetuin [PDF]

, 1992
Fetuins are among the major plasma proteins, yet their biological role has remained elusive. Here we report the molecular cloning of rat fetuin and the sequence analysis of a full-length clone, RF619 of 1456 bp with an open reading frame of 1056 bp ...
Albrecht G. J., Brown W. M., Cam A., Cayatte A. J., Christie D. L., Cohen P., Colclasure G. C., Coughlin J. P., Davis L. G., Dziegielewska K. M., Dziegielewska K. M., Dziegielewska K. M., Edge A. S. B., Haasemann M., Heijne G., Hortin G., Jones S. E., Kellermann J., Laemmli U. K., Lee C. C., Lewis J. G., Mizuno M., Mollgard K., Muller-Esterl W., Oss C. J., Pedersen K. O., Puck T. T., Rawlings N. D., Rohrlich S. T., Sambrook J., Sanger F., Sbraccia P., Schultze H. E., Strauss E. C., Triffitt J. T., Yang F., Yet M. G.   +36 more
core   +1 more source